12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PRT062607: Development discontinued

Biogen Idec disclosed in its 3Q12 earnings conference call that it and partner Portola discontinued development of PRT062607 to treat RA because the compound "did not meet the stringent target product profile to...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >